How Much Does Farxiga (Dapagliflozin) Cost in Connecticut in 2026?

Connecticut Retail Pricing for Farxiga in 2026

The average cash-pay price for a 30-day supply of Farxiga 10 mg at Connecticut retail pharmacies sits near $620 in 2026. That figure tracks closely with AstraZeneca's national list price and reflects minimal state-level variation. Without insurance or discount programs, this monthly cost places Farxiga among the more expensive oral diabetes and cardio-renal medications on the market.

Why the Price Is What It Is

Farxiga remains patent-protected, and no FDA-approved generic dapagliflozin exists as of May 2026. AstraZeneca holds exclusivity, which keeps retail pricing anchored to the branded list. The FDA-approved prescribing information for dapagliflozin covers three distinct indications: type 2 diabetes mellitus, heart failure with reduced ejection fraction, and chronic kidney disease [1]. Each approval expanded the eligible patient pool, but the absence of generic competition maintains a single price floor.

How CT Compares to National Averages

Connecticut pharmacy pricing tends to mirror or slightly exceed the national median for branded SGLT2 inhibitors. A 2023 analysis of SGLT2 inhibitor utilization published in Diabetes Care found that out-of-pocket costs remain a primary barrier to adherence, with patients paying more than $50 per month being 28% less likely to refill at 6 months [2]. Connecticut's comparatively higher cost of living can compound that burden, making savings programs and insurance coverage particularly relevant for residents.

Connecticut Medicaid Coverage for Dapagliflozin

Connecticut Medicaid, administered through HUSKY Health (Connecticut's Medicaid managed care program), covers Farxiga with prior authorization. The PA requirement means your prescriber must document medical necessity before the state plan will approve the claim. This typically involves showing that first-line therapy (usually metformin for type 2 diabetes) was tried or is contraindicated.

What the Prior Authorization Requires

Most Connecticut Medicaid PA requests for Farxiga require documentation of a confirmed diagnosis (type 2 diabetes, HFrEF, or CKD stage 2 to 4), evidence of first-line treatment failure or intolerance, and current lab values including eGFR and HbA1c. Turnaround runs 24 to 72 hours in standard cases. Urgent requests can be expedited within 24 hours.

Clinical Evidence Supporting Approval

The clinical case for dapagliflozin in heart failure is strong. The DAPA-HF trial (N=4,744) demonstrated that dapagliflozin 10 mg reduced the composite of worsening heart failure or cardiovascular death by 26% compared to placebo (HR 0.74, 95% CI 0.65 to 0.85, P<0.001) over a median 18.2 months of follow-up [3]. This trial enrolled patients with heart failure and reduced ejection fraction regardless of diabetes status, and the benefit was consistent across both diabetic and non-diabetic subgroups.

The DAPA-CKD trial (N=4,304) showed a 39% reduction in the composite of sustained eGFR decline, end-stage kidney disease, or renal/cardiovascular death (HR 0.61, 95% CI 0.51 to 0.72, P<0.001) [4]. Dr. Hiddo Heerspink, DAPA-CKD principal investigator, stated: "The magnitude of benefit was consistent irrespective of the presence or absence of type 2 diabetes, suggesting dapagliflozin provides kidney protection through mechanisms beyond glucose lowering" [4].

These outcomes inform why state Medicaid programs, including Connecticut's, have progressively broadened coverage criteria for SGLT2 inhibitors beyond diabetes alone.

Insurance Coverage Across Connecticut Plans

Commercial insurance plans in Connecticut generally cover Farxiga, though tier placement and cost-sharing structures vary. Most major carriers operating in the state place dapagliflozin on formulary tier 3 (preferred brand) or tier 4 (non-preferred brand), which determines your copay or coinsurance.

Major CT Carriers and Typical Tier Status

Anthem Blue Cross Blue Shield, ConnectiCare, Aetna, and UnitedHealthcare all maintain Connecticut-specific formularies. Anthem and Aetna typically list Farxiga as a tier 3 preferred brand for members with type 2 diabetes who have tried metformin. ConnectiCare plans sold on Access Health CT (the state exchange) often require step therapy documentation. UnitedHealthcare formularies may place it at tier 3 or tier 4 depending on the specific plan purchased.

Step Therapy and Exceptions

Step therapy protocols are common. A 2022 American Diabetes Association Standards of Care update recommended SGLT2 inhibitors as preferred second-line agents for patients with type 2 diabetes and established atherosclerotic cardiovascular disease, heart failure, or CKD [5]. The 2024 ADA Standards of Care further reinforced this positioning, noting that "for patients with T2D and established heart failure or CKD, SGLT2 inhibitor therapy is recommended independent of A1C" [5]. This guideline language gives prescribers strong ground for formulary exception requests when step therapy is required.

If your plan denies coverage, your prescriber can submit a formulary exception citing ADA guidelines and the relevant trial data. Most Connecticut insurers respond to exception requests within 5 to 10 business days.

The AstraZeneca Savings Card Program

AstraZeneca offers a manufacturer savings card for Farxiga that can reduce copays for commercially insured patients. Eligible patients may pay as little as $0 per 30-day fill, with a maximum annual benefit that AstraZeneca adjusts periodically. The card is not valid for patients covered by Medicare, Medicaid, Tricare, or other federal or state government programs.

Eligibility and Activation

To qualify, you need active commercial insurance that covers Farxiga (even at a high copay tier). Uninsured patients are not eligible for the copay card but may qualify for AstraZeneca's separate patient assistance program, AZ&ME, which provides free medication to qualifying individuals earning below 400% of the federal poverty level.

How It Works at the Pharmacy Counter

Present the savings card as a secondary payer at any Connecticut retail pharmacy. The pharmacist processes your insurance first, and the card covers a portion or all of the remaining copay. The card typically resets each calendar year. Keep in mind that savings cards do not apply to deductible accumulation under most plan designs, a distinction that matters for high-deductible health plan members.

Compounded Dapagliflozin in Connecticut

Licensed 503A compounding pharmacies in Connecticut can legally prepare compounded dapagliflozin formulations. Section 503A of the Federal Food, Drug, and Cosmetic Act permits state-licensed pharmacies to compound medications based on valid individual prescriptions [6]. Connecticut law aligns with this federal framework.

What 503A Compounding Means in Practice

A 503A pharmacy compounds a specific prescription for a specific patient, as opposed to 503B outsourcing facilities that produce larger batches. In Connecticut, compounding pharmacies must hold a valid state pharmacy license and comply with USP <795> standards for non-sterile compounding. Compounded dapagliflozin may come in different dosage forms (capsules, suspensions) than the brand tablet.

Cost and Quality Considerations

Pricing for compounded dapagliflozin varies significantly by pharmacy. Some 503A pharmacies advertise substantially lower costs than brand Farxiga. Three important caveats apply. First, compounded medications are not FDA-approved and do not undergo the same bioequivalence testing as branded or generic products [6]. Second, insurance plans rarely cover compounded versions when a commercially available equivalent exists. Third, potency and consistency depend entirely on the compounding pharmacy's quality controls.

The FDA's guidance on compounding states that compounded drugs "are not FDA-approved" and that the agency "generally defers to state authorities regarding the day-to-day regulation of state-licensed pharmacies that compound" [6]. Patients considering this route should discuss it with their prescriber and verify the pharmacy's accreditation status (PCAB accreditation is a strong quality signal, though not mandatory in Connecticut).

Telehealth Access to Farxiga in Connecticut

Connecticut permits telehealth prescribing of Farxiga. A prescriber licensed in Connecticut can evaluate you via video or audio visit and write a prescription for dapagliflozin if clinically appropriate. Post-pandemic telehealth expansions in Connecticut solidified audio-visual parity rules, meaning insurers must cover telehealth visits at the same rate as in-person visits under state law.

What a Telehealth Prescribing Visit Looks Like

Your provider will review your medical history, current medications, relevant lab work (HbA1c, eGFR, serum creatinine, potassium), and cardiovascular risk profile. Baseline labs drawn within the prior 3 months are generally sufficient. If dapagliflozin is appropriate, the provider can e-prescribe to any Connecticut pharmacy.

Monitoring After Initiation

SGLT2 inhibitors require periodic lab monitoring. The Kidney Disease: Improving Global Outcomes (KDIGO) 2024 guidelines recommend checking eGFR and serum potassium within 2 to 4 weeks of starting an SGLT2 inhibitor, then at regular intervals [7]. An initial eGFR dip of up to 30% is expected and generally reversible. Dr. Katherine Tuttle, executive director for research at Providence Health Care, has noted: "The early eGFR decline seen with SGLT2 inhibitors reflects hemodynamic changes in the kidney, not nephrotoxicity, and is actually a marker of long-term renal benefit" [7].

Connecticut telehealth platforms can order follow-up labs at local Quest or Labcorp draw sites, making remote management practical for stable patients.

Strategies to Lower Your Farxiga Cost in Connecticut

Several approaches can reduce what you actually pay for dapagliflozin in Connecticut, depending on your insurance status and income level.

For Commercially Insured Patients

The AstraZeneca savings card is the most direct path to lower copays. Pair it with a preferred pharmacy (check your plan's pharmacy network for tier pricing). Some plans offer 90-day mail-order fills at a lower per-unit cost than 30-day retail fills.

For Uninsured or Underinsured Patients

AstraZeneca's AZ&ME patient assistance program provides Farxiga at no cost to qualifying patients. Income limits typically sit at 400% of the federal poverty level ($62,400 for an individual in 2026). Application requires proof of income, a valid prescription, and prescriber attestation. GoodRx and RxAssist coupons may also reduce cash-pay prices at certain Connecticut pharmacies, though savings vary.

For Medicare Beneficiaries

Medicare Part D covers Farxiga on most formularies, though tier placement affects cost-sharing. The Inflation Reduction Act's $2,000 annual out-of-pocket cap on Part D spending (effective 2025) limits total annual exposure for Medicare beneficiaries [8]. Patients who reach the cap pay $0 for all remaining covered drugs for the rest of the calendar year. For a $620-per-month medication, many patients will hit that cap within the first few months.

For Medicaid Enrollees

Connecticut Medicaid enrollees with approved prior authorization typically pay $0 to $3 per fill, depending on their specific HUSKY plan tier. The PA process is the primary barrier, not cost.

When Dapagliflozin May Not Be the Right Choice

Not every patient with type 2 diabetes, heart failure, or CKD is a candidate for dapagliflozin. The FDA label contraindicates use in patients on dialysis and advises caution in those with a history of diabetic ketoacidosis [1]. SGLT2 inhibitors carry a class risk of genital mycotic infections (occurring in approximately 5% to 8% of female patients and 3% to 5% of male patients in clinical trials) and may increase the risk of urinary tract infections [1]. Volume depletion can occur, particularly in elderly patients or those on loop diuretics.

Patients with eGFR below 20 mL/min/1.73m² should generally not initiate dapagliflozin for glycemic control, though the DAPA-CKD data supported initiation for CKD benefit down to eGFR 25 [4]. Your provider will weigh these factors against the documented cardiovascular and renal benefits when deciding if Farxiga is appropriate for your specific clinical profile.

The DECLARE-TIMI 58 trial (N=17,160) found that dapagliflozin did not significantly reduce MACE (major adverse cardiovascular events) in the broad type 2 diabetes population but did reduce the composite of cardiovascular death or hospitalization for heart failure by 17% (HR 0.83, 95% CI 0.73 to 0.95, P=0.005) [9]. This finding shaped the FDA's heart failure indication and explains why insurers may approve Farxiga more readily for patients with established heart failure than for those with diabetes alone.